HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
April 01, 2024 16:10 ET | HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
November 14, 2023 07:00 ET | HCW Biologics, Inc
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
HCW Logo_Full_Color_600x_JPEG (2).jpg
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 08, 2023 07:30 ET | HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
HCW Logo_Full_Color_600x_JPEG (2).jpg
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
November 01, 2023 07:30 ET | HCW Biologics, Inc
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
September 06, 2023 07:30 ET | HCW Biologics, Inc
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 11, 2023 07:00 ET | HCW Biologics, Inc
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
June 14, 2023 07:30 ET | HCW Biologics, Inc
MIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
May 09, 2023 07:15 ET | HCW Biologics, Inc
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
April 27, 2023 07:40 ET | HCW Biologics, Inc
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
April 13, 2023 07:15 ET | HCW Biologics, Inc
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...